FDA

Biotech By Adam Feuerstein

A surprise FDA advisory panel imperils Fibrogen’s experimental anemia pill

Biotech By Adam Feuerstein

Sarepta wins new drug approval for patients with Duchenne muscular dystrophy, its third marketed treatment

First Opinion By Dorit R. Reiss

Is it time for the FDA to be independent?

First Opinion By Herschel Nachlis

Watch this FDA hearing on Thursday. It’ll help ease your Covid-19 anxieties

D.C. Diagnosis By STAT staff

STAT+ Conversations: The D.C. Diagnosis

Adam's Take By Adam Feuerstein

Do surprise drug rejections signal a more conservative FDA? Don’t bet on it

Adam's Take By Adam Feuerstein

Applied Therapeutics’ muted response to a clinical hold speaks volumes

Adam's Take By Adam Feuerstein

FDA refuses application for HIV drug from CytoDyn, raising more questions about its credibility

Biotech By Adam Feuerstein

Zogenix wins approval for new drug to treat rare type of childhood epilepsy

Adam's Take By Adam Feuerstein

CytoDyn says lead HIV drug was not filed for FDA approval, as previously claimed

Pharma By Adam Feuerstein

Bristol’s MS drug approval is good news for shareholders but patients will have to wait

Pharmalot By Ed Silverman

Pharmalittle: Rise in drug costs for large employers slows; experimental TB vaccine proves effective

Health By Andrew Joseph

New Vertex cystic fibrosis drug approved, extending treatments to 90% of patients

Pharmalot By Ed Silverman

FDA bid to bolster generic competition and combat shortages isn’t working — yet

Pharmalot By Ed Silverman

Pharmalittle: Judge orders pause in suits against Purdue and Sacklers; Teva must face opioid trial

First Opinion By Michael Cohen-Wolkowiez and Kanecia Zimmerman

FDA’s research guidance will help take guesswork out of drug dosing in newborns

Pharmalot By Ed Silverman

Pharmalittle: Mallinckrodt mulls restructuring as opioid trial nears; the next FDA commissioner will be …

Pharmalot By Ed Silverman

Pharmalittle: Two drug makers may settle opioid case; FDA hands Sarepta a surprising setback

First Opinion By Elizabeth Baker

FDA should use its existing program to qualify new tools for drug safety testing

Biotech By Adam Feuerstein

Sarepta stumbles on FDA rejection of a new drug to treat Duchenne muscular dystrophy

First Opinion By Robert M. Califf

Novartis violated FDA’s sacred principle: In God we trust, all others must bring data

First Opinion By Jane Horvath

State drug importation programs will work with the FDA, not outside of it

Pharmalot By Ed Silverman

Scott Gottlieb walks through the revolving door to the Pfizer board

Adam's Take By Adam Feuerstein

The FDA erred in approving new women’s libido drug; don’t reward Palatin Technologies

First Opinion By Scott Brunner

FDA’s overreach will harm compounding pharmacies and the patients they serve